Phase 2Not yet recruitingPriority 3 · Moderate priorityNCT07279584
Golidocitinib Combined With GemOx in RR PTCL
Plain-language summary
This trial is testing golidocitinib for patients with various types of peripheral T-cell lymphoma (PTCL) whose disease has come back or stopped responding to prior treatment. This is a Phase 2 trial, which means researchers are studying how well the treatment works and monitoring for side effects. This trial does not currently have sites in the United States. The trial is not yet open for recruitment.
Who can join (key eligibility)
- Age 18 Years or older
- Lymphoma came back or did not respond to prior treatment
- Must be well enough for treatment (adequate performance status)
Final eligibility is determined by the trial team. This list is a starting point only.
What's being tested
golidocitinib (DRUG): 150mg qd po | GEMOX (DRUG): Gemcitabine: 1000mg/m2, d1; Oxaliplatin:100mg/m2, d1
golidocitinib, GEMOX
- Treatment length
- Ask the trial team for details
- Visit frequency
- Ask the trial team for details